261 related articles for article (PubMed ID: 16428745)
21. Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice.
Tobias J; Svennerholm AM; Carlin NI; Lebens M; Holmgren J
Vaccine; 2011 Nov; 29(48):8863-9. PubMed ID: 21983363
[TBL] [Abstract][Full Text] [Related]
22. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.
Lásaro MO; Luiz WB; Sbrogio-Almeida ME; Nishimura LS; Guth BE; Ferreira LC
Infect Immun; 2004 Nov; 72(11):6480-91. PubMed ID: 15501779
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.
Chakraborty S; Harro C; DeNearing B; Ram M; Feller A; Cage A; Bauers N; Bourgeois AL; Walker R; Sack DA
Clin Vaccine Immunol; 2016 Jan; 23(1):55-64. PubMed ID: 26581889
[TBL] [Abstract][Full Text] [Related]
24. Oral immunization of a live attenuated Escherichia coli strain expressing a holotoxin-structured adhesin-toxoid fusion (1FaeG-FedF-LTA₂:5LTB) protected young pigs against enterotoxigenic E. coli (ETEC) infection.
Ruan X; Zhang W
Vaccine; 2013 Mar; 31(11):1458-63. PubMed ID: 23375979
[TBL] [Abstract][Full Text] [Related]
25. Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection.
Ouwehand AC; ten Bruggencate SJ; Schonewille AJ; Alhoniemi E; Forssten SD; Bovee-Oudenhoven IM
Br J Nutr; 2014 Feb; 111(3):465-73. PubMed ID: 23930950
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
[TBL] [Abstract][Full Text] [Related]
27. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.
Darsley MJ; Chakraborty S; DeNearing B; Sack DA; Feller A; Buchwaldt C; Bourgeois AL; Walker R; Harro CD
Clin Vaccine Immunol; 2012 Dec; 19(12):1921-31. PubMed ID: 23035175
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
[TBL] [Abstract][Full Text] [Related]
29. Intradermally Administered Enterotoxigenic Escherichia coli Vaccine Candidate MecVax Induces Functional Serum Immunoglobulin G Antibodies against Seven Adhesins (CFA/I and CS1 through CS6) and Both Toxins (STa and LT).
Garcia CY; Seo H; Sack DA; Zhang W
Appl Environ Microbiol; 2022 Feb; 88(4):e0213921. PubMed ID: 34936832
[TBL] [Abstract][Full Text] [Related]
30. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.
Harro C; Chakraborty S; Feller A; DeNearing B; Cage A; Ram M; Lundgren A; Svennerholm AM; Bourgeois AL; Walker RI; Sack DA
Clin Vaccine Immunol; 2011 Oct; 18(10):1719-27. PubMed ID: 21852546
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine.
Jertborn M; Ahrén C; Holmgren J; Svennerholm AM
Vaccine; 1998; 16(2-3):255-60. PubMed ID: 9607039
[TBL] [Abstract][Full Text] [Related]
33. Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli.
Qadri F; Ahmed T; Ahmed F; Bhuiyan MS; Mostofa MG; Cassels FJ; Helander A; Svennerholm AM
Infect Immun; 2007 May; 75(5):2269-74. PubMed ID: 17296752
[TBL] [Abstract][Full Text] [Related]
34. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres.
Tacket CO; Reid RH; Boedeker EC; Losonsky G; Nataro JP; Bhagat H; Edelman R
Vaccine; 1994 Nov; 12(14):1270-4. PubMed ID: 7856290
[TBL] [Abstract][Full Text] [Related]
35. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group.
Savarino SJ; Hall ER; Bassily S; Brown FM; Youssef F; Wierzba TF; Peruski L; El-Masry NA; Safwat M; Rao M; El Mohamady H; Abu-Elyazeed R; Naficy A; Svennerholm AM; Jertborn M; Lee YJ; Clemens JD
J Infect Dis; 1999 Jan; 179(1):107-14. PubMed ID: 9841829
[TBL] [Abstract][Full Text] [Related]
36. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates.
Tobias J; Svennerholm AM
Appl Microbiol Biotechnol; 2012 Mar; 93(6):2291-300. PubMed ID: 22350259
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates.
Sincock SA; Hall ER; Woods CM; O'Dowd A; Poole ST; McVeigh AL; Nunez G; Espinoza N; Miller M; Savarino SJ
Vaccine; 2016 Jan; 34(2):284-291. PubMed ID: 26597148
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age.
Qadri F; Ahmed T; Ahmed F; Bradley Sack R; Sack DA; Svennerholm AM
Vaccine; 2003 Jun; 21(19-20):2394-403. PubMed ID: 12744870
[TBL] [Abstract][Full Text] [Related]
39. Antibodies derived from an enterotoxigenic Escherichia coli (ETEC) adhesin tip MEFA (multiepitope fusion antigen) against adherence of nine ETEC adhesins: CFA/I, CS1, CS2, CS3, CS4, CS5, CS6, CS21 and EtpA.
Nandre RM; Ruan X; Duan Q; Sack DA; Zhang W
Vaccine; 2016 Jun; 34(31):3620-5. PubMed ID: 27228947
[TBL] [Abstract][Full Text] [Related]
40. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
